Company / R&D per Share
Arrowhead Pharmaceuticals R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$4.88
FY2025
5-year range
$1.24 / $4.88
FY2021-FY2025
Trend
+3.6%
vs FY2024
Sector context
#34 of 208
Health Care
What the data says
Arrowhead Pharmaceuticals's r&d per share of $4.88 is higher than 84% of companies in the Health Care sector (FY2025). R&D per Share has increased for 3 consecutive years, from $1.24 in FY2022 to $4.88 in FY2025.
Based on SEC 10-K filings.
4.88 in FY2025 with a 5-year CAGR of +29.3%. Top quartile in the Health Care sector.
Improved from $1.95 to $4.88 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +58.1%
- 5-Year CAGR
- +29.3%
- 10-Year CAGR
- -
Sector benchmark
Top 16% in Health CareTop 16% of 208This company $4.88 Sector average $28.82
▼
-83.1% below sector average
Key checks
Key Insights
- Arrowhead Pharmaceuticals's r&d per share has grown for 3 consecutive years.
- In FY2025, r&d per share increased 3.6% year-over-year.
- Ranks #34 out of 208 companies in the Health Care sector.
- Lowest r&d per share in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score 0.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.88 | +3.6% |
| FY2024 | $4.71 | +142.1% |
| FY2023 | $1.95 | +57.6% |
| FY2022 | $1.24 | -38.7% |
| FY2021 | $2.02 | +49.4% |
| FY2020 | $1.35 | +134.6% |
| FY2019 | $0.58 | -30.8% |
| FY2018 | $0.83 | +22.6% |
| FY2017 | $0.68 | -35.0% |
| FY2016 | $1.04 | +555.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026